In this sense, a case of regression of non-irradiated metastases from melanoma NY-ESO+ after receiving palliative RT combined with immunotherapy (anti-CTLA-4/ipilimumab) has been recently described by Postow et al. (57). Here, CTLA4 is linked to melanoma.